Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens (original) (raw)

Abstract

Background & aim: Supplementation with probiotic Bifidobacteria or Lactobacilli or the combination of both, has been shown to maintain a healthy balance of bacterial flora in the intestinal lumen. A placebocontrolled, crossover, self-comparing clinical study evaluated the probiotic effects of Lactobacillus fermentum P.C.C. (ProBioPCC) on gastrointestinal bacterial flora. Methods: This 8-week trial comprised an initial lead-in week with no study intervention, a 3-week treatment phase (taking ProBio, 1 capsule/day), a 1-week washout phase, a 3-week control phase (taking placebo, 1 capsule/day), followed by a final week of washout. Thirty healthy adults (age: 25e43 years) having no gastrointestinal diseases were recruited into the study. Stool samples were collected once at each experimental week, and cultured for counting colonies of total anaerobic bacteria, Lactobacillus spp., Bifidobacterium spp., and Clostridium perfringens. Results: We found significantly increased colony counts of Lactobacillus spp. In stool samples after the treatment phase (p < 0.05). Colony counts of probiotic Bifidobacterium spp. were significantly increased with the study intervention (p < 0.05), while those of harmful C. perfringens were reduced (p < 0.05). Ratios of Bifidobacterium spp. to total anaerobic bacteria and to C. perfringes were increased significantly (p < 0.05). The bacteria colony counts and ratios returned toward baselines during and after the placebo control phase. In order to confirm the increase of intestinal probiotics was due to oral administration of ProBioPCC, we further demonstrated that L. fermentum P.C.C. strain was resistant against simulated gastric acid and bile in vitro. Conclusions: Our data indicate that ProBioPCC is effective in decreasing C. perfringens and increasing ratio of Bifidobacterium spp. to total anaerobic bacteria in healthy humans.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (22)

  1. Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, et al. Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colo- nized Helicobacter pylori. Am J Clin Nutr 2004;80:737e41.
  2. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004;79:261e7.
  3. Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004;18:299e313.
  4. Scientific concepts of functional foods in Europe. Consensus document. Br J Nutr 1999;81(Suppl. 1):S1e27.
  5. Orrhage K, Nord CE. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res 2000;26:95e111.
  6. Vanderhoof JA, Young RJ. Role of probiotics in the management of patients with food allergy. Ann Allergy Asthma Immunol 2003;90:99e103.
  7. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 2004;70:1176e81.
  8. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis 2004;5:64e7.
  9. Elmer GW. Probiotics: "living drugs". Am J Health Syst Pharm 2001;58:1101e9.
  10. LeBlanc JG, Silvestroni A, Connes C, Juillard V, de Giori GS, Piard JC, et al. Reduction of non-digestible oligosaccharides in soymilk: application of engi- neered lactic acid bacteria that produce alpha-galactosidase. Genet Mol Res 2004;3:432e40.
  11. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermenta- tion. Am J Clin Nutr 2001;73:415Se20S.
  12. Grizard D, Barthomeuf C. Non-digestible oligosaccharides used as prebiotic agents: mode of production and beneficial effects on animal and human health. Reprod Nutr Dev 1999;39:563e88.
  13. Lankaputhra WEV, Shah NP. Survival of Lactobacillus acidophilus and Bifido- bacterium spp in the presence of acid and bile salts. Cult Dairy Prod J 1995;30:2e7.
  14. Akyol S, Mas MR, Comert B, Ateskan U, Yasar M, Aydogan H, et al. The effect of antibiotic and probiotic combination therapy on secondary pancreatic infec- tions and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas 2003;26:363e7.
  15. Holzapfel WH, Haberer P, Snel J, Schillinger U, Huis in't Veld JH. Overview of gut flora and probiotics. Int J Food Microbiol 1998;41:85e101.
  16. Howard JC, Reid G, Gan BS. Probiotics in surgical wound infections: current status. Clin Invest Med 2004;27:274e81.
  17. Fox CH, Dang G. Probiotics in the prevention and treatment of diarrhea. J Altern Complement Med 2004;10:601e3.
  18. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73:430Se6S.
  19. Rasic JL, Kurmann JA. Bifidobacteria and their role. Microbiological, nutritional- physiological, medical and technological aspects and bibliography. Experientia Suppl 1983;39:1e29.
  20. Tamura N, Norimoto M, Yoshida K, Hirayama C, Nakai R, Takagi A. Alteration of fecal bacterial flora following oral administration of bifidobacterial prepara- tion. Gastroenterol Jpn 1983;18:47e55.
  21. Linsalata M, Russo F, Berloco P, Caruso ML, Matteo GD, Cifone MG, et al. The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa. Helicobacter 2004;9:165e72.
  22. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998;80(Suppl. 1):S147e71.